publication date: Jun. 20, 2014
SWOG earlier this week started to accrue patients to Lung-MAP, a clinical trial for second-line treatment of non-small cell lung cancer.
The trial, also called Lung Cancer Master Protocol or SWOG S1400, uses the patients’ tumor characteristics to select one of five targeted therapies, comparing them with active control in each arm.
Lung-MAP is funded by a public-private partnership, which combines NCI’s limited funds with those of commercial sponsors, pointing to a new way of pooling resources to conduct faster, more efficient registration trials.
|Conversation with The Cancer Letter|
What $34,000 per Patient Buys in Lung-MAP
The Cancer Letter asked David Wholley, director of research partnerships for the Foundation for the National Institutes of Health, to explain the novel scientific and administrative structure of Lung-MAP.
“For the first five drugs that are going into the trial, NCI is putting in about $24 million, and companies are putting in about $55 million. This would cover the costs for all of the drugs to complete testing through phase III,” he said.
|90-Ton Cyclotron Delivered To University of Maryland, Touching Off D.C.-Area Proton Radiation Competition|
BALTIMORE—Constructed in Germany, shipped to the port of Baltimore, and driven through downtown during the night, the 90-ton cyclotron arrived at the University of Maryland’s Proton Treatment Center.
|340B Drug Discount Program |
HRSA Defends Orphan Drug Rule
Cancer survivors face higher medical costs and productivity losses when compared to people without a cancer history, according to a CDC study published June 13.
Patricia LoRusso named associate director of innovative medicine at Yale Cancer Center
Corrine Augelli-Szafran named director of chemistry at Southern Research Institute
Sandeep Reddy named chief medical officer of Caris Life Sciences
Hiromitsu Ota receives award from Wistar Institute
Yeshiva University and Montefiore Health System agree on new management structure for Albert Einstein College of Medicine
Dana-Farber Cancer Institute and Trovagene Inc. begin collaboration
Eli Lilly and Qiagen announce plan to co-develop assay panels
Bayer Pharma AG and arGEN-X collaborate to develop therapeutic antibodies